Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients

Journal of Vascular Access

Volumn 9, Issue 4, 2008, Pages 248-253

  Costa, Elísio ^a,b,c   Rocha, S ^b,c   Rocha Pereira, P ^c,d   Castro, E ^b,c   Reis, F ^e   Teixeira, F ^e   Miranda, V ^f   Do Sameiro Faria, M ^f   Loureiro, A ^f   Quintanilha, A ^b   Belo, L ^b,c   Santos Silva, A ^b,c  

^a CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f SA   (Portugal)

Author keywords

Chronic renal failure; D dimers; Fibrinolytic activity; Vascular access

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; D DIMER; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ERYTHROPOIETIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERRIN; ANTIANEMIC AGENT; AUTACOID; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR; SERPINE1 PROTEIN, HUMAN; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTERIOVENOUS SHUNT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CENTRAL VENOUS CATHETER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LEUKOCYTE; MALE; NEUTROPHIL; RISK FACTOR; THROMBOCYTE; THROMBOGENESIS; VASCULAR ACCESS; BLOOD; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PORTUGAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; THROMBOSIS;

AGED; ARTERIOVENOUS SHUNT, SURGICAL; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEMATINICS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PORTUGAL; RECEPTORS, INTERLEUKIN-2; RENAL DIALYSIS; RISK ASSESSMENT; SERUM ALBUMIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 60549110919     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980800900405     Document Type: Article

References (23)

1. Santoro A. Confounding factors in the assessment of delivered hemodialysis dose. Kidney Int 2000; 77 (suppl): S19-27.
2. Ifudu O, Mayers JD, Cohen LS, et al. Correlates of vascular access and nonvascular access-related hospitalizations in hemodialysis patients. Am J Nephrol 1996; 16: 118-23.
3. Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-90.
4. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000; 36: 68-74.
5. Mandolfo S, Piazza W, Galli F. Central venous catheter and the hemodialysis patient: a difficult symbiosis. J Vasc Access 2002; 3: 64-73.
6. Schindler R, Senf R, Frei U. Influencing the inflammatory response of haemodialysis patients by cytokine elimination using large-pore membranes. Nephrol Dial Transplant 2002; 17: 17-9.
7. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-16.
8. Fishbane S. Hyporesponsiveness to recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2000; 29: 545-8.
9. Costa E, Lima M, Alves JM, et al. Inflammation, T-cell phenotype and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28: 268-75.
10. Hung C, Chen Y, Chou C, Yang C. Nutritional and inflammatory markers in the prediction of mortality in Chinese hemodialysis patients. Nephron Clin Pract 2005; 100: c20-6.
11. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002; 61 (suppl): S99-102.
12. Agras PI, Baskin E, Cengiz N, Kirazli S, Saatci U, Ozbek N. Global fibrinolytic capacity in children on dialysis. Thromb Res 2005; 115: 185-9.
13. Yu A, Egberg N, Jacobson SH. Haemostatic complications in haemodialysis patients: effect of type of vascular access and dialysis filter. Scand J Clin Lab Invest 2003; 63: 127-34.
14. Kanno Y, Kobayashi K, Takane H, et al. Elevation of plasma D-dimer is closely associated with venous thrombosis produced by double-lumen catheter in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 1224-7.
15. Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int Suppl 2007; 107: S4-9.
16. Shireman PK, McCarthy WJ, Pearce WH, Shively VP, Cipollone M, Kwaan HC. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. J Vasc Surg 1997; 25: 157-64.
17. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.
18. Schoenmakers S, Reitsma P, Spek C. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005; 34: 30-7.
19. Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2: 113-21.
20. Segarra A, Chacon P, Martinez-Eyarre C, et al. Circulating levels of plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-63.
21. Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 2004; 24: 495-501.
22. Pawlak K, Zolbach K, Borawski J, et al. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thromb Res 2008, doi:10.1016/ j.thromres.2008.02.012.
23. Pradhan AD, LaCroix AZ, Langer RD, et al. Tissue plasminogen activator antigen and d-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004; 110: 292-300.